{"id":"NCT03336450","sponsor":"Shire","briefTitle":"Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting","officialTitle":"A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-23","primaryCompletion":"2020-10-13","completion":"2020-10-13","firstPosted":"2017-11-08","resultsPosted":"2021-09-14","lastUpdate":"2021-09-14"},"enrollment":3,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nervous System Diseases"],"interventions":[{"type":"DRUG","name":"SHP615","otherNames":["MHOS","Midazolam hydrochloride oromucosal solution"]},{"type":"DRUG","name":"MHOS/SHP615","otherNames":[]}],"arms":[{"label":"SHP615","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting. This study is open-label extension for patients who completed the SHP615-301 study and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.","primaryOutcome":{"measure":"Efficacy: Number of Participants With Therapeutic Success","timeFrame":"From start of study drug administration up to 30 minutes post-dose","effectByArm":[{"arm":"SHP615","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":23,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":3},"commonTop":["Somnolence","Nausea","Vomiting","Upper respiratory tract infection"]}}